Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 23111-00-4
2. 3-carbamoyl-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium Chloride
3. 8xm2xt8vwi
4. Nicotinamide Ribose Chloride
5. Nicotinamide Riboside (chloride)
6. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride
7. Ss-nicotinamide Riboside
8. Unii-8xm2xt8vwi
9. Srt647;niagen
10. Schembl17315043
11. Mfcd27952781
12. Hy-123033a
13. Ac-29830
14. Ws-00064
15. Cs-0098615
16. F20757
17. F20758
18. A901913
19. Eh-301 Component Nicotinamide Riboside Chloride
20. Pyridinium, 3-carbamoyl-1-beta-d-ribofuranosyl-, Chloride
21. Pyridinium, 3-(aminocarbonyl)-1-beta-d-ribofuranosyl-, Chloride
22. Pyridinium, 3-carbamoyl-1-.beta.-d-ribofuranosyl-, Chloride
23. Pyridinium, 3-(aminocarbonyl)-1-.beta.-d-ribofuranosyl-, Chloride
24. 3-carbamoyl-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-iumchloride
25. 3-carbamoyl-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridinium Chloride
Molecular Weight | 290.70 g/mol |
---|---|
Molecular Formula | C11H15ClN2O5 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 3 |
Exact Mass | 290.0669493 g/mol |
Monoisotopic Mass | 290.0669493 g/mol |
Topological Polar Surface Area | 117 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 314 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Nicotinamide Riboside Chloride
About the Company : Bulat Pharmaceutical is a fast growing pharmaceutical company, founded in the year 2017, Bulat Pharmaceutical is engaged in the manufacturing and sales of high quality APIs and Int...
Nicotinamide Riboside Chloride
About the Company : Mulei (Wuhan) New Material Technology is a scientific and technological company integrating product research and development, manufacturing and trading of chemical intermediates, s...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Niagen (nicotinamide riboside chloride) is an oral supplement which significantly increases NAD+ levels, it is being investigated in Ataxia Telangiectasia.
Lead Product(s): Nicotinamide Riboside Chloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: Niagen
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2024
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ChromaDex's NRC Gets FDA ODD and RPD for Ataxia Telangiectasia
Details : Niagen (nicotinamide riboside chloride) is an oral supplement which significantly increases NAD+ levels, it is being investigated in Ataxia Telangiectasia.
Brand Name : Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 07, 2024
Details:
ChromaDex has invested over $35 million in investigating and marketing NR as Niagen, which has received regulatory acceptance in the United States, Canada, the European Union, and Australia.
Lead Product(s): Nicotinamide Riboside Chloride
Therapeutic Area: Endocrinology Brand Name: Niagen
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers i...
Details : ChromaDex has invested over $35 million in investigating and marketing NR as Niagen, which has received regulatory acceptance in the United States, Canada, the European Union, and Australia.
Brand Name : Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2020
10 Sep 2024
// BUSINESSWIRE
16 Jul 2024
// BUSINESSWIRE
13 Jun 2024
// BUSINESSWIRE
07 Jun 2024
// BUSINESSWIRE
07 Jun 2024
// Justine Ra PHARMACEUTICAL TECHNOLOGY
https://www.pharmaceutical-technology.com/news/chromadex-wins-orphan-designation-for-rare-ataxia-drug/
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?